Chinese venture BeiGene is aiming to transform itself in the wake of a US IPO, hoping to attract more partnering deals as it focuses on progressing its pipeline and fast-tracking its anticancer assets, amid an improving Chinese environment for new drug development.
BEIJING – During an April 20 opening bell ceremony at New York's NASDAQ Stock Exchange, BeiGene (Beijing) Co. Ltd. executives expressed optimism towards biotech growth in China.
Following an official listing on the bourse on Feb.3, the Beijing-based biotech had held off on the ceremony until after...
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
